Primary Sclerosing Cholangitis Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Primary Sclerosing Cholangitis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Primary Sclerosing Cholangitis’s therapeutic pipeline.

Primary Sclerosing Cholangitis Therapeutic Pipeline Review

Primary Sclerosing Cholangitis Therapeutic Pipeline Review

The report "Primary Sclerosing Cholangitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis. Primary sclerosing cholangitis is a liver disease in which the bile ducts gradually decrease in size due to swelling and scarring. Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. Many people with primary sclerosing cholangitis do not get symptoms, especially in the early stages of the disease. The most common symptoms are fatigue, pruritus, jaundice and yellowing of the skin and eyes. The symptoms of this disease can be treated with antibiotics, vitamins and medications to control itching, improve bile flow etc. Complete Report is Available at http://www.rnrmarketresearch.com/primary-sclerosing-cholangitis-pipeline-review-h1-2015-market-report.html.

It also reviews key players involved in the therapeutic development for Primary Sclerosing Cholangitis and special features on late-stage and discontinued projects. Companies discussed in this Primary Sclerosing Cholangitis Pipeline Review H1 2015 report include Biotie Therapies Corp., ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc. and Shire Plc.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=269565 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases

  •     Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
  •     Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
  •     Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases

Table of Contents

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2015 7
Number of Products under Development for Primary Sclerosing Cholangitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Primary Sclerosing Cholangitis - Pipeline by Biotie Therapies Corp., H1 2015 12
Primary Sclerosing Cholangitis - Pipeline by ChemoCentryx, Inc., H1 2015 13
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 14
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences, Inc., H1 2015 15
Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 16
Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Primary Sclerosing Cholangitis Therapeutics - Recent Pipeline Updates, H1 2015 37

Inquiry Before Buying at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269565. (This is a premium report priced at US$2000 for a single user License.)

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2015 7
Number of Products under Development for Primary Sclerosing Cholangitis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs.

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website